investorscraft@gmail.com

Orchestra BioMed Holdings, Inc. (OBIO)

Previous Close
$2.78
Sector Valuation Confidence Level
High
Valuation methodValue, $Upside, %
Artificial intelligence (AI)126.824462
Intrinsic value (DCF)0.00-100
Graham-Dodd Methodn/a
Graham Formulan/a

Company Information

150 Union Square Drive
New Hope, PA 18938
United States
Phone: 215 862 5797
Industry: Biotechnology
Sector: Healthcare
CEO: Mr. David P. Hochman
Full Time Employees: 70

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

HomeMenuAccount